highly significantP < 0.0001
Survival benefit and safety profile Kaplan–Meier survival analysis revealed a highly significant intergroup difference (log-rank test, P < 0.0001).
Survival benefit and safety profile Kaplan–Meier survival analysis revealed a highly significant intergroup difference (log-rank test, P < 0.0001).
At this time point, the 177 Lu-PSMA617 + genistein group exhibited a 78.1% reduction in tumor volume compared to 177 Lu-PSMA617 monotherapy, while the 177 Lu-PSMA617 + baicalein group showed a 50.2% reduction, demonstrating a strong trend of enhanced efficacy, although these differences did not reach statistical significance ( P > 0.05) (Fig. 4 B).